Comparison
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738 vs 17q12 Recurrent Deletion Syndrome C6011081
Clinical comparison between 3 Hydroxyisobutyryl Coa Hydrolase Deficiency and 17q12 Recurrent Deletion Syndrome for differential diagnosis and treatment planning.
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
A metabolic disorder affecting the breakdown of amino acids. It may cause neurological problems, developmental delay, and metabolic disturbances. Treatment focuses on dietary management and supportive interventions.
17q12 Recurrent Deletion Syndrome C6011081
A genetic condition from deletion on chromosome 17. Can involve developmental delays, neurological features, and potential kidney involvement. Management requires regular monitoring and supportive therapies.
6 comparison axes
Onset
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
0-3
17q12 Recurrent Deletion Syndrome C6011081
0-null
Onset patterns differ
Severity
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
severe
17q12 Recurrent Deletion Syndrome C6011081
moderate
Different severity levels
Chronic
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
Chronic
17q12 Recurrent Deletion Syndrome C6011081
Chronic
Differing course
Communicable
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
No
17q12 Recurrent Deletion Syndrome C6011081
No
Different transmission
Body System
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
metabolic
17q12 Recurrent Deletion Syndrome C6011081
congenital
Same/different system
Category
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
metabolic
17q12 Recurrent Deletion Syndrome C6011081
genetic
Different category
Bottom line
3-hydroxyisobutyryl-coa-hydrolase-deficiency-C0342738 and 17q12-recurrent-deletion-syndrome-C6011081 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738 | 17q12 Recurrent Deletion Syndrome C6011081 | Discriminating power |
|---|---|---|---|
| Developmental delay | May occur with metabolic and neurological disturbance. | May occur with congenital neurodevelopmental features. | Low |
| Metabolic disturbance | Suggested by the amino-acid breakdown disorder description. | Not described as a primary metabolic disorder. | Moderate |
| Kidney involvement | Not established in the supplied description. | Potential kidney involvement is described. | Moderate |
When to favor each condition
Choose 3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738 when
Early metabolic or neurological presentation
Supplied onset is 0–3 years and severity is severe.
Moderate
Suspected amino-acid metabolism disorder
The description centers on impaired amino-acid breakdown.
Moderate
Need for dietary metabolic management
Treatment is described as dietary and supportive.
Moderate
Choose 17q12 Recurrent Deletion Syndrome C6011081 when
Congenital or variable-onset developmental features
Onset is listed as 0–null and category is genetic.
Moderate
Suspected chromosomal deletion
The condition is defined by deletion on chromosome 17.
High
Developmental features with possible kidney findings
Kidney involvement is specifically mentioned.
Moderate
How key tests differ
| Test | 3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738 | 17q12 Recurrent Deletion Syndrome C6011081 | Interpretation |
|---|---|---|---|
| Metabolic evaluation | May be relevant; exact abnormalities are not established here. | No specific metabolic result is supplied. | An abnormal result is not itself a diagnosis. |
| Chromosomal microarray or deletion testing | Not the defining test in the supplied data. | May support a chromosome 17 deletion when clinically indicated. | Genetic confirmation requires specialist interpretation. |
| Kidney assessment | No kidney finding is established here. | Monitoring may be considered because involvement is possible. | Findings need clinical correlation; cutoffs are not supplied. |
Prognosis comparison
3 Hydroxyisobutyryl Coa Hydrolase Deficiency C0342738
- Outcome
- Described as severe and chronic; individual outcome is not established.
- Factors
- Neurological problems, developmental delay, and metabolic disturbances may influence course.
17q12 Recurrent Deletion Syndrome C6011081
- Outcome
- Described as moderate and chronic; individual outcome is not established.
- Factors
- Developmental, neurological, and possible kidney features may influence needs.
Time frame: Long-term course is expected, but no specific timeline is established.
Etiology, severity, complications, and response to supportive care require clinician interpretation.
Complications comparison
| Complication | Presentation |
|---|---|
| Neurological problems | Described as possible and potentially severe. Neurological features may occur. Specific complications and frequency are not established. |
| Developmental impairment | Developmental delay may occur. Developmental delays may occur. Severity and trajectory require individual assessment. |
| Organ involvement | Metabolic disturbance is the described focus. Potential kidney involvement is described. Do not infer additional organs without evidence. |
Patient education highlights
- HighDifferent causes
One is a metabolic disorder; the other is a chromosomal deletion. Neither is communicable.
- HighSpecialist care
Management is supportive, with dietary care for the metabolic condition and monitoring for the deletion syndrome.
- MediumUncertain details
Exact risks, laboratory cutoffs, and outcomes are not established from these source data.